Zacks: Analysts Expect Corvus Pharmaceuticals Inc (CRVS) Will Post Earnings of -$0.40 Per Share

Equities research analysts expect Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to announce earnings per share of ($0.40) for the current quarter, according to Zacks. Zero analysts have made estimates for Corvus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.39) and the lowest estimate coming in at ($0.41). Corvus Pharmaceuticals reported earnings per share of ($0.63) during the same quarter last year, which would suggest a positive year over year growth rate of 36.5%. The firm is expected to announce its next quarterly earnings report on Thursday, May 2nd.

On average, analysts expect that Corvus Pharmaceuticals will report full-year earnings of ($1.66) per share for the current year, with EPS estimates ranging from ($1.72) to ($1.60). For the next year, analysts expect that the firm will post earnings of ($1.81) per share, with EPS estimates ranging from ($1.83) to ($1.78). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Corvus Pharmaceuticals.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.10.

Several equities research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, March 28th. ValuEngine cut Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Finally, Wedbush cut their price target on Corvus Pharmaceuticals from $19.00 to $11.00 and set an “outperform” rating for the company in a report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $11.94.

Several large investors have recently bought and sold shares of CRVS. Paloma Partners Management Co acquired a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth about $58,000. Rhumbline Advisers boosted its holdings in shares of Corvus Pharmaceuticals by 44.1% in the fourth quarter. Rhumbline Advisers now owns 18,203 shares of the company’s stock worth $67,000 after buying an additional 5,570 shares during the period. Prudential Financial Inc. boosted its holdings in shares of Corvus Pharmaceuticals by 15.0% in the fourth quarter. Prudential Financial Inc. now owns 21,545 shares of the company’s stock worth $79,000 after buying an additional 2,805 shares during the period. Citadel Advisors LLC acquired a new position in shares of Corvus Pharmaceuticals in the third quarter worth about $182,000. Finally, Credit Suisse AG acquired a new position in shares of Corvus Pharmaceuticals in the third quarter worth about $194,000. Institutional investors own 85.71% of the company’s stock.

CRVS traded down $0.04 during midday trading on Monday, hitting $3.88. 1,491 shares of the company’s stock traded hands, compared to its average volume of 79,662. Corvus Pharmaceuticals has a one year low of $3.22 and a one year high of $13.91.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Featured Article: How to calculate the annual rate of depreciation

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.